--- title: "Entera Bio (ENTX) news: offering" url: "https://aibio.space/companies/entera-bio/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ENTX offering news: Entera Bio closes $275.0 million private placement at $2.04 a share. Entera Bio Ltd. (NASDAQ: ENTX), Israel." --- ENTX Entera Bio Ltd. NASDAQ · Israel # Entera Bio (ENTX) news ENTX offering news Financings · 2026-07-28 ## [Entera Bio closes $275.0 million private placement at $2.04 a share](https://aibio.space/news/entera-bio-closes-275-0-million-private-placement-2-04-share/) BVF Partners-affiliated funds are among the buyers and gain the right to name two directors. Entera says it will use the money to support a Phase 3 study of EB613. ## Latest Entera Bio news 1. 2026-04-03 Financings [Entera Bio sells 7,827,789 units to BVF-affiliated funds at $1.2775 each in private placement](https://aibio.space/news/entera-bio-sells-7-827-789-units-bvf-affiliated-funds-1-2775-each/) Entera Bio sold 7,827,789 units to funds affiliated with BVF Partners LP at $1.2775 a unit, with the closing on April 2, 2026. The 8-K names no placement agent or bank, and the company's 10-K says its cash covers operations only through the middle of the third quarter of 2026. 2. 2025-03-17 Financings [Entera Bio signs OPKO oral GLP-1/glucagon deal and sells OPKO shares for $8.0 million](https://aibio.space/news/entera-bio-signs-opko-oral-glp-1-glucagon-deal-sells-opko-shares-8-0/) OPKO bought 3,685,226 Entera ordinary shares at about $2.17. Entera will hold the money in escrow to fund its 40% share of development costs. Entera can opt out after Phase 1. 3. 2025-03-17 Financings [OPKO Health buys 3,685,226 Entera Bio shares at $2.17 in obesity collaboration](https://aibio.space/news/opko-health-buys-3-685-226-entera-bio-shares-2-17-obesity/) The two companies will hold 60% and 40% ownership interests in an oral GLP-1/glucagon program. Entera says the proceeds will fund its 40% share through Phase 1. 4. 2025-01-10 Financings [Entera Bio adds up to 30,000,000 shares to its at-the-market program](https://aibio.space/news/entera-bio-adds-up-30-000-000-shares-market-program/) Entera Bio Ltd. nearly used up the 5,000,000 shares first registered with Leerink Partners. The new supplement covers an additional block under the same sales agreement. ## Entera Bio at a glance - **Ticker**: ENTX - **Listing**: NASDAQ - **Country**: Israel - **Cash, Jun 30, 2026**: $11.3 million ### Related companies - [Purple Biotech](https://aibio.space/companies/purple-biotech/) TASE: PPBT - [PolyPid](https://aibio.space/companies/polypid/) NASDAQ: PYPD - [PRF Technologies](https://aibio.space/companies/prf-technologies/) NASDAQ: PRFX - [Silexion Therapeutics](https://aibio.space/companies/silexion-therapeutics/) NASDAQ: SLXN - [Can-Fite BioPharma](https://aibio.space/companies/can-fite-biopharma/) TASE: CANF - [Sol-Gel Technologies](https://aibio.space/companies/sol-gel-technologies/) NASDAQ: SLGL - [Redhill Biopharma](https://aibio.space/companies/redhill-biopharma/) NASDAQ: RDHL - [NeuroSense Therapeutics](https://aibio.space/companies/neurosense-therapeutics/) NASDAQ: NRSN ### Also on NASDAQ - [Adlai Nortye Group](https://aibio.space/companies/adlai-nortye/) ANL - [Tempest Therapeutics](https://aibio.space/companies/tempest-therapeutics/) TPST - [Relmada Therapeutics](https://aibio.space/companies/relmada-therapeutics/) RLMD - [Rezolute](https://aibio.space/companies/rezolute/) RZLT - [Syndax Pharmaceuticals](https://aibio.space/companies/syndax-pharmaceuticals/) SNDX - [Tango Therapeutics](https://aibio.space/companies/tango-therapeutics/) TNGX ## What Entera Bio does Entera Bio Ltd. is a clinical-stage company developing first-in-class oral tablet formats of peptides and protein replacement therapies. It focuses on chronic conditions where frequent injections create a major treatment gap. Its N-Tab platform is designed to stabilize large hydrophilic peptides in the gastrointestinal tract and promote their absorption into the bloodstream. Its most advanced product candidate, EB613, is oral teriparatide, or oral PTH(1-34), being developed as the first oral, osteoanabolic tablet for osteoporosis. EB613 is being developed under a 505(b)(2) application that references Forteo, which the FDA first approved in 2002. The text says EB613 completed a Phase 2, 6-month, 161-patient, placebo-controlled study that met its biomarker and BMD endpoints. The company also reports post-hoc analyses of that Phase 2 trial. Its pipeline additionally includes oral peptides targeting GLP-1/Glucagon and GLP-2. | Product or program | What it is | Stage | |---|---|---| | EB613 | Oral teriparatide tablet for osteoporosis under a 505(b)(2) application | Phase 2 completed | | Oral GLP-1/Glucagon and GLP-2 peptides | First-in-class oral peptides in the company pipeline | | Summarised from the company's [10-K filed Mar 27, 2026](https://www.sec.gov/Archives/edgar/data/1638097/000117891326001797/zk2634461.htm). ## Entera Bio annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$42,000](https://www.sec.gov/Archives/edgar/data/1638097/000117891326001797/) | [$181,000](https://www.sec.gov/Archives/edgar/data/1638097/000117891326001797/) | | Research and development | [$6.0 million](https://www.sec.gov/Archives/edgar/data/1638097/000117891326001797/) | [$4.5 million](https://www.sec.gov/Archives/edgar/data/1638097/000117891326001797/) | | Net income (loss) | [-$11.4 million](https://www.sec.gov/Archives/edgar/data/1638097/000117891326001797/) | [-$9.5 million](https://www.sec.gov/Archives/edgar/data/1638097/000117891326001797/) | | Cash from operations | [-$7.4 million](https://www.sec.gov/Archives/edgar/data/1638097/000117891326001797/) | [-$6.8 million](https://www.sec.gov/Archives/edgar/data/1638097/000117891326001797/) | | Cash and equivalents | [$7.1 million](https://www.sec.gov/Archives/edgar/data/1638097/000117891326003947/) | [$8.7 million](https://www.sec.gov/Archives/edgar/data/1638097/000117891326001797/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $11.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Entera Bio Has Entera Bio raised money recently? Our latest story on this, dated Jul 28, 2026: "Entera Bio closes $275.0 million private placement at $2.04 a share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/entera-bio-closes-275-0-million-private-placement-2-04-share/). What is the ticker symbol of Entera Bio? Entera Bio Ltd. trades under the ticker ENTX on NASDAQ. Where is Entera Bio listed? Entera Bio Ltd. is listed on NASDAQ. What is the SEC CIK of Entera Bio? The SEC Central Index Key (CIK) for Entera Bio Ltd. is 1638097. Its filings are on SEC EDGAR. How many shares does Entera Bio have outstanding? 173,141,831 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-07. Which country or territory is Entera Bio listed under? Our directory records Entera Bio Ltd. under Israel. What does Entera Bio do? Our directory classifies Entera Bio Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Entera Bio? The ISIN recorded for Entera Bio Ltd. is IL0011429839. Does aibio.space cover Entera Bio? aibio.space lists Entera Bio Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Entera Bio incorporated? SEC records list its state or country of incorporation as L3. What does Entera Bio develop? Entera Bio Ltd. is a clinical-stage company developing first-in-class oral tablet formats of peptides and protein replacement therapies. It focuses on chronic conditions where frequent injections create a major treatment gap. What is EB613 from Entera Bio? EB613: Oral teriparatide tablet for osteoporosis under a 505(b)(2) application Stage: Phase 2 completed. What is Oral GLP-1/Glucagon and GLP-2 peptides from Entera Bio? Oral GLP-1/Glucagon and GLP-2 peptides: First-in-class oral peptides in the company pipeline Stage: stage not stated. What was Entera Bio's revenue last year? $42,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Entera Bio profitable? Entera Bio Ltd. reported a net loss of $11.4 million for the fiscal year ended Dec 31, 2025, and used $7.4 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Entera Bio Members talk about Entera Bio (ENTX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Entera Bio, newest first. Each line links the filing it comes from. 1. 2026-07-28 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1638097/000117891326003617/zk2635734.htm) 2. 2026-04-03 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1638097/000117891326002001/zk2634965.htm) 3. 2025-03-17 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1638097/000117891325000857/exhibit_99-1.htm) 4. 2025-01-10 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1638097/000117891325000079/zk2532538.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ENTX on TradingView](https://www.tradingview.com/symbols/NASDAQ-ENTX/). ## SEC filings and registration - **SEC name**: Entera Bio Ltd. - **CIK**: 1638097 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: ENTX (Nasdaq) - **State or country of incorporation**: L3 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM, 9112002 - **Phone**: 972-2-532-7151 - **Shares outstanding**: 173,141,831 as of 2026-08-03 (10-Q filed 2026-08-07) ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1638097/000117891326004771/zk2636187.htm) filed 2026-10-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1638097/000117891326004720/zk2636199.htm) filed 2026-10-06 - [S-3](https://www.sec.gov/Archives/edgar/data/1638097/000117891326004221/zk2635989.htm) filed 2026-08-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1638097/000117891326004178/zk2635983.htm) filed 2026-08-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1638097/000117891326003947/zk2635812.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1638097/000117891326003946/zk2635891.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1638097/000117891326003617/zk2635734.htm) filed 2026-07-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1638097/000117891326003510/zk2635691.htm) filed 2026-07-16 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001638097), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Entera Bio Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ENTX, recorded under Israel. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Entera Bio Ltd. - **Ticker**: ENTX - **Listing**: NASDAQ - **Country or territory**: Israel - **Business scope**: Pharmaceuticals: Major - **ISIN**: IL0011429839 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ENTX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/entera-bio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Entera Bio (ENTX) news: offering", 2026-10-31, https://aibio.space/companies/entera-bio/